Stock itci.
8 Wall Street analysts have issued 1-year price targets for Intra-Cellular Therapies' shares. Their ITCI share price targets range from $62.00 to $101.00. On average, they predict the company's stock price to reach $78.67 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price.
Mar 6, 2023 · Read why ITCI stock is a Hold. Intra-Cellular Therapeutics develops small molecule drugs targeting the CNS for neuropsychiatric and neurological disorders. Read why ITCI stock is a Hold. According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.Nov 7, 2023 · by Zacks Equity Research Published on November 07,2023. The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric ... Tsai is hardly the only bull on this stock; ITCI has a unanimous Strong Buy consensus rating supported by 9 analyst reviews. The average price target of $68.67 gives a 12% upside potential from the current share price of $61.05. (See ITCI stock analysis on TipRanks)NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has announced a Psychopharmacologic Drugs Advisory …
Nov. 08. CI. RBC Trims Price Target on Intra-Cellular Therapies to $76 From $77, Keeps Outperform Rating. Nov. 03. MT. Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q3 Revenue $126.2M. Nov. 02. MT. Transcript : Intra-Cellular Therapies, Inc., Q3 2023 Earnings Call, Nov 02, 2023.
ITCI reported total revenues of $126.2 million for Q3 2023, compared to $71.9 million for the same period in 2022. ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can ...
home / stock / itci / itci news. RSS . ITCI ITCI Quote ITCI Short ITCI News ITCI Articles ITCI Message Board. February, 24 2021 07:30 AM ... Feb. 24, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...Apr 26, 2017 · ITCI - place your bets With a huge upcoming catalyst - CAPLYTA PDUFA due December 17th, 2021, it will make or break this stock - with an approval from the FDA, I expect pt of around 57, with possibility to hit all-time high within a year from CAPLYTA launch. ITCI Stock Overview. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system …8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | December 30, 2022
Shares of Intra-Cellular Therapies stock opened at $61.37 on Friday. The company has a market cap of $5.91 billion, a PE ratio of -38.12 and a beta of 1.04. The business has a 50 day moving ...
What is Intra-Cellular Therapies Inc (ITCI)'s stock price today? The current price of ITCI is $59.42. The 52 week high of ITCI is $67.05 and 52 week low is $42.01. When is next earnings date of Intra-Cellular Therapies Inc (ITCI)?
Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report. ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report. Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report.At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Disruption hit MTR services to Hong Kong’s airport for about an hour on Sunday, because of a fault with the baggage handling system at Airport station. Services were back to normal by 1.25pm. The total journey time on the Airport Express from Hong Kong station to AsiaWorld-Expo station was extended by five to 10 minutes, according to …NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has announced a Psychopharmacologic Drugs Advisory …Find the latest Intra-Cellular Therapies, Inc. (ITCI) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
Intra-Cellular Therapies Inc. research and ratings by Barron's. View ITCI revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.As of April 23, 2023, the average one-year price target for Intra-Cellular Therapies is 77.93. The forecasts range from a low of 56.56 to a high of $102.90. The average price target represents an ...Discover historical prices for ITCI stock on Yahoo Finance. View daily, weekly or monthly format back to when Intra-Cellular Therapies, Inc. stock was issued. Nov 23, 2022 · Shares of Intra-Cellular Therapies (ITCI) have gained 18.4% over the past four weeks to close the last trading session at $52.87, but there could still be a solid upside left in the stock if short ... Mar 21, 2022 · Covering ITCI for Jefferies, analyst Andrew Tsai writes: “In 2022, we think ITCI stock could break all-time highs despite a challenging tape, as Caplyta scripts are accelerating earlier (and ... home / stock / itci / itci news. RSS . ITCI ITCI Quote ITCI Short ITCI News ITCI Articles ITCI Message Board. February, 24 2021 07:30 AM ... Feb. 24, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...Real time Intra-Cellular Therapies (ITCI) stock price quote, stock graph, news & analysis.
Intra-Cellular Therapies, Inc. (ITCI) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 62.84 +1.47 (+2.40%) At close: 04:00PM EST. 60.44 -2.40 (-3.82%) After hours:...
A. The latest price target for Intra-Cellular Therapies ( NASDAQ: ITCI) was reported by RBC Capital on Friday, November 3, 2023. The analyst firm set a price target for 76.00 …ITCI Intra-Cellular. 10/02/23 RBC Capital Intra-Cellular Caplyta patent extension granted, says RBC Capital 08/04/23 Cantor Fitzgerald Intra-Cellular price target raised to $98 from $90 at Cantor Fitzgerald 07/06/23 Needham ... Create up to 12 portfolios with 150 stocks each, and see how active they are in market news. ...Intra-Cellular Therapies Inc. Common Stock (ITCI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Intra-Cellular Therapies Inc’s trailing 12-month revenue is $365.8 million with a -50.4% profit margin. Year-over-year quarterly sales growth most recently was 99.3%. Analysts expect adjusted earnings to reach $-2.089 per share for the current fiscal year. Intra-Cellular Therapies Inc does not currently pay a dividend.NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced a poster presentation on its PDE1 inhibitor program at the ongoing 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, which is being held from April 10 - 15, 2021.ITCI has a Quality Grade of D, ranking ahead of 18.25% of graded US stocks. ITCI's asset turnover comes in at 0.08 -- ranking 278th of 682 Pharmaceutical Products stocks. …
ITCI reported total revenues of $126.2 million for Q3 2023, compared to $71.9 million for the same period in 2022. ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can ...
Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ITCI stock stock is $78.5, which predicts an increase of 34.05%. The lowest target is $62 and the highest is $101. On average, analysts rate ITCI stock stock as a strong buy.
Headquartered in Chelmsford, Massachusetts, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a sample exploration and management solutions provider for the life science market. On November 23, 2022 ...The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY. ITCI - Intra-Cellular Therapies Inc - Stock screener for investors and traders, financial visualizations.0001193125-20-214163.txt : 20200810 0001193125-20-214163.hdr.sgml : 20200810 20200810081722 ACCESSION NUMBER: 0001193125-20-214163 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENTShort selling ITCI is an investing strategy that aims to generate trading profit from Intra-Cellular Therapies as its price is falling. ITCI shares are trading up $2.60 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender.Intra-Cellular Therapies Market Cap: 5.69B, Enterprise value: 5.39B, P/E: -21.66, PEG ratio: -0.97, EPS: -1.54, Revenue: 418.10M, EBITDA: -172.56M, ...In addition, Intra-Cellular has granted the underwriters a 30-day option to purchase up to an additional 921,300 shares of common stock. In connection with the offering, shares of Intra-Cellular common stock will commence trading on the NASDAQ Global Select Market tomorrow morning under the ticker "ITCI."3 “Strong Buy” Stocks Showing Monster Growth. by Harold Vazquez. March 21, 2022Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?May 4, 2023 · Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Get Intra-Cellular Therapies Inc (ITCI.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsNov 23, 2022 · Shares of Intra-Cellular Therapies (ITCI) have gained 18.4% over the past four weeks to close the last trading session at $52.87, but there could still be a solid upside left in the stock if short ... ITCI Stock Overview. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system …Instagram:https://instagram. bat tobacco stockhound labs stocksquarespace net worthnasdaq grts Find the latest Intra-Cellular Therapies, Inc. (ITCI) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. pre market gainersla guia de principiantes para iniciar tu propio negocio A. The latest price target for Intra-Cellular Therapies ( NASDAQ: ITCI) was reported by RBC Capital on Friday, November 3, 2023. The analyst firm set a price target for 76.00 … how much gold coin worth NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the completion of its previously announced underwritten public offering of 9,523,810 shares of its common …Intra-Cellular Therapies (ITCI) shares soared 16.4% in the last trading session to close at $55.73. The move was backed by solid volume with far more shares changing hands than in a normal session.